Malignant pleural mesothelioma and epidermal growth factor receptor (EGF-R). Relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody.
AffiliationCRC Department of Medical Oncology, Christie Hospital and Holt Radium Institute, Manchester, UK.
MetadataShow full item record
AbstractThe expression of epidermal growth factor receptor (EGF-R) in 34 formalin fixed paraffin embedded specimens of malignant mesothelioma was examined using the F4 antibody. Eight samples of reactive pleura showed homogenous cytoplasmic staining with the antibody. EGF-R positive cells (greater than or equal to 5%) were found in 68% of the mesotheliomas examined. EGF-R positivity was more commonly seen in the epithelial histological subtype than in the sarcomatous or mixed subtypes. Patients with less than 5% of mesothelioma cells staining positive for EGF-R had a significantly shorter survival (median 299 days) compared with patients whose tumours had a greater number of cells positive for EGF-R (median 446 days) (P = 0.04). However, when the histological subgroup was also taken into consideration (epithelial type had a significantly longer survival than the sarcomatous or mixed) the survival difference in relation to EGF-R positivity was no longer significant (P = 0.08). EGF-R could not be used to distinguish between malignant and benign mesothelial tissue and was not an independent prognostic factor for survival.
CitationMalignant pleural mesothelioma and epidermal growth factor receptor (EGF-R). Relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody. 1990, 61 (6):924-6 Br J Cancer
JournalBritish Journal of Cancer
- Epidermal growth factor receptor and transforming growth factor alpha expression in papillary and nonpapillary renal cell carcinoma: correlation with metastatic behavior and prognosis.
- Authors: Uhlman DL, Nguyen P, Manivel JC, Zhang G, Hagen K, Fraley E, Aeppli D, Niehans GA
- Issue date: 1995 Aug
- WT1 mutation in malignant mesothelioma and WT1 immunoreactivity in relation to p53 and growth factor receptor expression, cell-type transition, and prognosis.
- Authors: Kumar-Singh S, Segers K, Rodeck U, Backhovens H, Bogers J, Weyler J, Van Broeckhoven C, Van Marck E
- Issue date: 1997 Jan
- Immunohistochemical staining for vimentin and keratin in malignant mesothelioma.
- Authors: Churg A
- Issue date: 1985 May
- Heparin-binding epidermal growth factor-like growth factor isoforms and epidermal growth factor receptor/ErbB1 expression in bladder cancer and their relation to clinical outcome.
- Authors: Kramer C, Klasmeyer K, Bojar H, Schulz WA, Ackermann R, Grimm MO
- Issue date: 2007 May 15
- Immunohistochemical detection of epidermal growth factor receptor lacks prognostic significance for breast carcinoma.
- Authors: Göhring UJ, Ahr A, Scharl A, Weisner V, Neuhaus W, Crombach G, Holt JA
- Issue date: 1995 Jul-Aug